Navigation Links
Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
Date:7/29/2008

se 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate the T cells of a patient's own immune system, to eliminate cancer cells. Micromet is developing blinatumomab in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293, which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Three additional BiTE antibodies, targeting CD33, CEA and MCSP, are in preclinical development. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, a human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
4. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
5. ViroPharma to Present at Three Upcoming Healthcare Conferences
6. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
7. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. Alfacell Corporation to Present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... HILL, N.C. , Feb. 27, 2015 ... over the past decade but one thing hasn,t changed: ... MSLs to build relationships with Key Opinion Leaders. ... recognized as the most valuable type of interaction, field ... limits on their KOL interactions. This is just one ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... from a pre-clinical study published in the ... ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ... (a checkpoint inhibitor), suppression of tumor growth was ... when treating certain hematologic cancers and solid tumors ...
(Date:2/27/2015)... TEL-AVIV , Israele, February 27, 2015 /PRNewswire/ ... continua nel suo sviluppo dell,innovativo sistema di monitoraggio ... il primo trial sull,uomo-   ... operante nello sviluppo di nuovo sistema per il ... congestizio (CHF), ha annunciato oggi di aver concluso ...
Breaking Medicine Technology:Improving the Management of MSL Teams to Create Value across a Diverse Set of Customers 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... ResMed Inc. (NYSE: RMD ) today announced results ... quarter ended September 30, 2011 was a record $314.8 million, ... basis) over the quarter ended September 30, 2010.  For the ... Largely as a result of currency exchange rate movements, net ...
... of the most crucial components of a successful new ... relationships with the FDA. However, while building a collegial and ... the FDA is not always an easy task, not doing ... study participant, a Regulatory Affairs Executive Director at a leading ...
Cached Medicine Technology:ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 2ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 3ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 4ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 5ResMed Inc. Announces Financial Results for the Quarter Ended September 30, 2011 6Recent Research Provides Formula for Timely Product Launch: Good Science + Effective FDA Relations 2
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 A study ... promising new gene therapy procedure for the treatment of ... in patients. Authored by Dr. Robert MacLaren, ... published in the Lancet Medical Journal on January 16, ... choroideremia, a rare genetic disorder that mostly affects men ...
(Date:2/28/2015)... February 28, 2015 Dr. Perry ... Coast area residents, recently announced a special offer for ... a treatment option for new and established patients at ... with a bright, white smile, Dr. Patel and his ... $299, marked down from the regular price of $450. ...
(Date:2/28/2015)... York, NY (PRWEB) February 28, 2015 On ... Phishing Kits Make It Easy For Scammers To Steal Your ... anyone can get their hands on a DIY phishing kit, ... But it also touched on another important point about how ... these kits are often implemented, “like compromising legitimate content management ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4
... FRIDAY, March 18 (HealthDay News) -- Obstructive sleep apnea may ... with enlarged prostates, a new study suggests. The study ... benign prostate enlargement (BPE) and reported nighttime urination (nocturia) at ... of same-age men who had no BPE and one or ...
... 18 (HealthDay News) -- Women in smoke-free homes and ... breast cancer, new research shows. U.S. researchers compared ... of breast cancer incidence and death. States with higher ... breast cancer deaths, particularly among younger premenopausal women. ...
... College of Radiology,s Imaging Network (ACRIN) and the ... (NCI) Clinical Trials Cooperative Group members, today announced ... programs. The groups plan to form ... new organization will include three areas of research ...
... with different terms to describe a clinical trial, parents were far ... called a "research study" than if it was called a "medical ... the former as safer, even though that was not necessarily the ... Human Research . Terms such as these are ...
... News) -- Anti-drug ads appear to be an effective way ... the United States, a new study has found. In ... Influence" anti-drug campaign, researchers analyzed the relationship between exposure to ... students in grades 8, 10 and 12. The campaign ...
... The federal Centers for Disease Control and Prevention ... Health & Hospitals System and Rush University Medical ... successful program aimed at preventing healthcare-associated infections, antibiotic ... The project, dubbed the Chicago Antimicrobial Resistance and ...
Cached Medicine News:Health News:Sleep Disorder May Spur Men to Head to Bathroom at Night 2Health News:Biomarker-driven science at the heart of new ACRIN-ECOG structure 2Health News:Biomarker-driven science at the heart of new ACRIN-ECOG structure 3Health News:Terminolgy matters in parents' willingness to enroll their children in research 2Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 2Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 3Health News:CDC, Cook County and Rush collaborate to research and prevent hospital infections 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: